Irradiated tumor cells

Irradiated tumor cells are malignant cells that have been treated with high doses of ionizing radiation to permanently arrest their growth while maintaining their cellular structure and antigenic profile. In clinical oncology, they are primarily utilized as the foundational component of whole-cell cancer vaccines, such as GVAX, which aim to trigger a broad, systemic immune response against a patient's specific tumor [NCI Drug Dictionary]. The irradiation process is designed to induce immunogenic cell death, facilitating the release of danger-associated molecular patterns (DAMPs) that recruit and activate the host's innate immune system [PMID: 30610226]. Once administered, these cells provide a diverse array of tumor-associated antigens and neoantigens to antigen-presenting cells, which subsequently prime cytotoxic T lymphocytes to identify and destroy viable cancer cells throughout the body [PMID: 25107453]. This therapeutic approach is intended to overcome the challenges of tumor heterogeneity by presenting multiple targets to the immune system simultaneously. While not a single molecular target, irradiated tumor cells represent a complex biological platform for personalized and allogeneic immunotherapy.

Other names

Irradiated cancer cellsWhole-cell tumor vaccineInactivated tumor cellsLethally irradiated tumor cells

Irradiated tumor cells serve as a polyvalent source of tumor-associated antigens (TAAs) and neoantigens. Upon administration, these cells are engulfed by antigen-presenting cells (APCs), such as dendritic cells, which process and present the antigens to T-cells. This process is often enhanced by the induction of immunogenic cell death (ICD) during irradiation, which releases danger signals (DAMPs) that stimulate the immune system to recognize and attack live tumor cells [PMID: 30610226, PMID: 25107453].